Chemical Nametagraxofusp-erzs
Dosage FormInjection (intravenous; 1,000 mcg/1 ml)
Drug ClassMiscellaneous antineoplastics
CompanyStemline Therapeutics, Inc.
Approval Year2018


  • To treat blastic plasmacytoid dendritic cell neoplasm in patients ≥ 2 years of age.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Elzonris (Tagraxofusp-erzs) Prescribing Information 2018Stemline Therapeutics, Inc., New York, NY
Document TitleYearSource
Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm.2019The New England Journal of Medicine